Repros Therapeutics Stock Price, News & Analysis (NASDAQ:RPRX)

$0.67 -0.01 (-1.47 %)
(As of 02/19/2018 04:00 PM ET)
Previous Close$0.68
Today's Range$0.67 - $0.68
52-Week Range$0.26 - $1.33
Volume251,700 shs
Average Volume473,590 shs
Market Capitalization$26.50 million
P/E Ratio-1.34
Dividend YieldN/A
Beta0.45

About Repros Therapeutics (NASDAQ:RPRX)

Repros Therapeutics logoRepros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company's Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

Receive RPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:RPRX
CUSIP76028H20
Phone+1-281-7193400

Debt

Debt-to-Equity RatioN/A
Current Ratio1.18%
Quick Ratio1.18%

Price-To-Earnings

Trailing P/E Ratio-1.34
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$50,000.00
Price / Sales530.10
Cash FlowN/A
Price / CashN/A
Book Value$0.24 per share
Price / Book2.79

Profitability

Trailing EPS($0.50)
Net Income$-17,270,000.00
Net Margins-4,242.73%
Return on Equity-894.22%
Return on Assets-230.71%

Miscellaneous

Employees24
Outstanding Shares39,560,000

Repros Therapeutics (NASDAQ:RPRX) Frequently Asked Questions

What is Repros Therapeutics' stock symbol?

Repros Therapeutics trades on the NASDAQ under the ticker symbol "RPRX."

How were Repros Therapeutics' earnings last quarter?

Repros Therapeutics Inc (NASDAQ:RPRX) released its earnings results on Monday, November, 13th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.24. The biotechnology company earned $0.30 million during the quarter. Repros Therapeutics had a negative return on equity of 894.22% and a negative net margin of 4,242.73%. View Repros Therapeutics' Earnings History.

When will Repros Therapeutics make its next earnings announcement?

Repros Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March, 29th 2018. View Earnings Estimates for Repros Therapeutics.

Where is Repros Therapeutics' stock going? Where will Repros Therapeutics' stock price be in 2018?

1 Wall Street analysts have issued 1 year price targets for Repros Therapeutics' shares. Their predictions range from $0.39 to $0.39. On average, they expect Repros Therapeutics' stock price to reach $0.39 in the next year. View Analyst Ratings for Repros Therapeutics.

Are investors shorting Repros Therapeutics?

Repros Therapeutics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 852,002 shares, a decrease of 34.8% from the January 12th total of 1,307,720 shares. Based on an average daily volume of 393,922 shares, the days-to-cover ratio is currently 2.2 days. Currently, 2.2% of the company's shares are sold short.

Who are some of Repros Therapeutics' key competitors?

Who are Repros Therapeutics' key executives?

Repros Therapeutics' management team includes the folowing people:

  • Patrick P. Fourteau, Chairman of the Board (Age 69)
  • Larry M Dillaha M.D., President, Chief Executive Officer, Director (Age 53)
  • Katherine A. Anderson CPA, Chief Financial Officer, Chief Accounting Officer, Secretary (Age 58)
  • Joachim F. Wernicke, Chief Medical Officer (Age 68)
  • Daniel F. Cain, Independent Director (Age 70)
  • Nola E. Masterson, Independent Director (Age 69)
  • Saira Ramasastry, Independent Director (Age 40)
  • Michael G. Wyllie Ph.D., Independent Director (Age 65)

Who owns Repros Therapeutics stock?

Repros Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.01%) and Kassirer Asset Management Corp (1.67%). View Institutional Ownership Trends for Repros Therapeutics.

Who sold Repros Therapeutics stock? Who is selling Repros Therapeutics stock?

Repros Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Repros Therapeutics.

Who bought Repros Therapeutics stock? Who is buying Repros Therapeutics stock?

Repros Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Kassirer Asset Management Corp. View Insider Buying and Selling for Repros Therapeutics.

How do I buy Repros Therapeutics stock?

Shares of Repros Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Repros Therapeutics' stock price today?

One share of Repros Therapeutics stock can currently be purchased for approximately $0.67.

How big of a company is Repros Therapeutics?

Repros Therapeutics has a market capitalization of $26.50 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-17,270,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Repros Therapeutics employs 24 workers across the globe.

How can I contact Repros Therapeutics?

Repros Therapeutics' mailing address is 2408 Timberloch Pl Ste B7, THE WOODLANDS, TX 77380-1021, United States. The biotechnology company can be reached via phone at +1-281-7193400 or via email at [email protected]


MarketBeat Community Rating for Repros Therapeutics (RPRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  279
MarketBeat's community ratings are surveys of what our community members think about Repros Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Repros Therapeutics (NASDAQ:RPRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.002.002.002.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $0.39$0.39$0.39$1.50
Price Target Upside: 2.63% upside2.63% upside2.63% upside279.75% upside

Repros Therapeutics (NASDAQ:RPRX) Consensus Price Target History

Price Target History for Repros Therapeutics (NASDAQ:RPRX)

Repros Therapeutics (NASDAQ:RPRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2017S&P Equity ResearchLower Price Target$0.49 -> $0.39N/AView Rating Details
7/21/2017LaidlawDowngradeBuy -> NeutralMediumView Rating Details
11/16/2016Ladenburg Thalmann Financial ServicesUpgradeNeutral -> BuyN/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Repros Therapeutics (NASDAQ:RPRX) Earnings History and Estimates Chart

Earnings by Quarter for Repros Therapeutics (NASDAQ:RPRX)

Repros Therapeutics (NASDAQ RPRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2018($0.32)N/AView Earnings Details
11/13/2017Q3 2017($0.28)($0.04)$0.30 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.22)($0.08)$0.01 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.15)($0.22)$0.01 millionViewN/AView Earnings Details
3/31/2017Q4 2016($0.17)($0.16)$0.01 millionViewN/AView Earnings Details
11/8/2016Q3 2016($0.18)($0.17)$0.01 millionViewN/AView Earnings Details
8/9/2016Q216($0.20)($0.18)$0.02 millionViewN/AView Earnings Details
5/10/2016Q1($0.22)($0.20)$0.02 millionViewN/AView Earnings Details
3/14/2016Q4($0.27)($0.26)$0.01 millionViewN/AView Earnings Details
11/9/2015Q3($0.29)($0.27)ViewN/AView Earnings Details
8/10/2015Q2($0.26)($0.32)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.35)ViewN/AView Earnings Details
3/16/2015Q414($0.34)($0.31)ViewN/AView Earnings Details
11/10/2014Q314($0.39)($0.32)ViewN/AView Earnings Details
8/11/2014($0.37)($0.38)ViewN/AView Earnings Details
5/12/2014Q114($0.35)($0.37)ViewN/AView Earnings Details
3/13/2014Q413($0.29)($0.31)ViewN/AView Earnings Details
11/7/2013Q3 2013($0.33)($0.26)ViewN/AView Earnings Details
8/7/2013Q213($0.40)($0.38)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.35)($0.41)ViewN/AView Earnings Details
3/18/2013Q412($0.28)($0.47)$0.00 million$0.00 millionViewN/AView Earnings Details
11/13/2012Q312($0.24)($0.30)ViewN/AView Earnings Details
8/13/2012Q2 2012($0.17)($0.21)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.18)($0.17)ViewN/AView Earnings Details
3/27/2012Q4 2011($0.34)($0.22)ViewN/AView Earnings Details
11/10/2011Q3 2011($0.35)($0.32)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.20)($0.30)ViewN/AView Earnings Details
5/16/2011Q1 2011($0.13)($0.20)ViewN/AView Earnings Details
3/28/2011Q4 2010($0.16)($0.13)ViewN/AView Earnings Details
11/10/2010Q3 2010($0.16)($0.13)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.16)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.18)ViewN/AView Earnings Details
3/15/2010Q4 2009($1.28)($0.23)ViewN/AView Earnings Details
11/9/2009Q3 2009($2.36)($2.64)ViewN/AView Earnings Details
8/17/2009Q2 2009($1.84)($2.34)ViewN/AView Earnings Details
5/11/2009Q1 2009($1.88)($1.78)ViewN/AView Earnings Details
3/16/2009Q4 2008($1.80)($1.55)ViewN/AView Earnings Details
11/10/2008Q3 2008($2.08)($2.06)ViewN/AView Earnings Details
8/11/2008Q2 2008($2.20)($1.90)ViewN/AView Earnings Details
5/9/2008Q1 2008($1.64)($2.10)ViewN/AView Earnings Details
3/17/2008Q4 2007($1.28)($1.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Repros Therapeutics (NASDAQ:RPRX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Repros Therapeutics (NASDAQ:RPRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Repros Therapeutics (NASDAQ RPRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.50%
Institutional Ownership Percentage: 13.58%
Insider Trades by Quarter for Repros Therapeutics (NASDAQ:RPRX)
Insider Trades by Quarter for Repros Therapeutics (NASDAQ:RPRX)

Repros Therapeutics (NASDAQ RPRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/9/2016Joseph PodolskiInsiderBuy20,000$1.60$32,000.00View SEC Filing  
2/18/2016Joseph PodolskiCEOBuy10,000$0.93$9,300.00View SEC Filing  
1/7/2016Joseph PodolskiCEOBuy11,677$1.18$13,778.8677,422View SEC Filing  
11/12/2014Joseph PodolskiCEOBuy4,700$9.42$44,274.00View SEC Filing  
11/12/2014Katherine AndersonCFOBuy3,500$9.41$32,935.00View SEC Filing  
8/14/2014Joseph PodolskiCEOBuy2,100$13.91$29,211.00View SEC Filing  
8/14/2014Katherine AndersonCFOBuy2,000$13.85$27,700.00View SEC Filing  
10/25/2013Joseph PodolskiCEOBuy3,000$18.03$54,090.00View SEC Filing  
10/25/2013Katherine AndersonCFOBuy1,000$17.90$17,900.00View SEC Filing  
10/10/2013Katherine AndersonCFOBuy1,000$23.77$23,770.005,375View SEC Filing  
2/1/2013Katherine AndersonCFOBuy1,000$11.89$11,890.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Repros Therapeutics (NASDAQ RPRX) News Headlines

Source:
DateHeadline
Short Interest in Repros Therapeutics Inc (RPRX) Declines By 34.8%Short Interest in Repros Therapeutics Inc (RPRX) Declines By 34.8%
www.americanbankingnews.com - February 12 at 4:08 AM
Reviewing Repros Therapeutics (RPRX) and Arena Pharmaceuticals (ARNA)Reviewing Repros Therapeutics (RPRX) and Arena Pharmaceuticals (ARNA)
www.americanbankingnews.com - February 2 at 3:32 PM
Repros Announces Negative Opinion From the EMA for EnclomipheneRepros Announces Negative Opinion From the EMA for Enclomiphene
finance.yahoo.com - January 26 at 4:10 PM
Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Repros Therapeutics Inc. In The ... - PR Newswire (press release)Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Repros Therapeutics Inc. In The ... - PR Newswire (press release)
www.prnewswire.com - January 10 at 7:22 AM
Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Repros Therapeutics Inc. In The Southern District Of Texas Houston DivisionMonteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Repros Therapeutics Inc. In The Southern District Of Texas Houston Division
finance.yahoo.com - January 9 at 3:21 PM
Repros Therapeutics Inc (NASDAQ:RPRX): Is Healthcare An Attractive Sector Play?Repros Therapeutics Inc (NASDAQ:RPRX): Is Healthcare An Attractive Sector Play?
finance.yahoo.com - December 30 at 7:31 AM
Financial Analysis: Repros Therapeutics (RPRX) and ArQule (ARQL)Financial Analysis: Repros Therapeutics (RPRX) and ArQule (ARQL)
www.americanbankingnews.com - December 25 at 7:29 PM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Repros Therapeutics, Inc. - RPRX - PR Newswire (press release)SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Repros Therapeutics, Inc. - RPRX - PR Newswire (press release)
www.prnewswire.com - December 19 at 7:10 AM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Repros Therapeutics, Inc. - RPRXSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Repros Therapeutics, Inc. - RPRX
finance.yahoo.com - December 18 at 3:21 PM
Repros Therapeutics (RPRX) Receives Feedback Following Oral Explanation with EMA - StreetInsider.comRepros Therapeutics (RPRX) Receives Feedback Following Oral Explanation with EMA - StreetInsider.com
www.streetinsider.com - December 17 at 7:16 AM
Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency - GlobeNewswire (press release)Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency - GlobeNewswire (press release)
globenewswire.com - December 16 at 7:06 AM
TG Therapeutics (TGTX) & Repros Therapeutics (RPRX) Head-To-Head ContrastTG Therapeutics (TGTX) & Repros Therapeutics (RPRX) Head-To-Head Contrast
www.americanbankingnews.com - December 15 at 1:36 PM
Allergan Inks Deal to Buy Texas-Based Repros Therapeutics - NasdaqAllergan Inks Deal to Buy Texas-Based Repros Therapeutics - Nasdaq
www.nasdaq.com - December 14 at 6:58 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors ... - Business Wire (press release)SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors ... - Business Wire (press release)
www.businesswire.com - December 13 at 6:52 AM
REPROS THERAPEUTICS INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of BuyoutREPROS THERAPEUTICS INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
finance.yahoo.com - December 13 at 6:52 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Repros Therapeutics Inc. to Allergan plc is Fair to ShareholdersSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Repros Therapeutics Inc. to Allergan plc is Fair to Shareholders
finance.yahoo.com - December 12 at 3:21 PM
Repros Therapeutics Inc.® Announces Acquisition by Allergan plc - GlobeNewswire (press release)Repros Therapeutics Inc.® Announces Acquisition by Allergan plc - GlobeNewswire (press release)
globenewswire.com - December 12 at 6:59 AM
Repros Therapeutics Inc.® Announces Acquisition by Allergan plcRepros Therapeutics Inc.® Announces Acquisition by Allergan plc
finance.yahoo.com - December 12 at 6:59 AM
Who Owns Most Of Repros Therapeutics Inc (RPRX)?Who Owns Most Of Repros Therapeutics Inc (RPRX)?
finance.yahoo.com - December 9 at 6:55 AM
Novelion Therapeutics (NVLN) & Repros Therapeutics (RPRX) Head-To-Head SurveyNovelion Therapeutics (NVLN) & Repros Therapeutics (RPRX) Head-To-Head Survey
www.americanbankingnews.com - December 5 at 9:32 PM
How Does Investing In Repros Therapeutics Inc (RPRX) Impact Your Portfolio?How Does Investing In Repros Therapeutics Inc (RPRX) Impact Your Portfolio?
finance.yahoo.com - November 30 at 3:21 PM
Today’s Research Reports on Trending Tickers: Incyte Corporation and Repros Therapeutics Inc.Today’s Research Reports on Trending Tickers: Incyte Corporation and Repros Therapeutics Inc.
finance.yahoo.com - November 21 at 9:59 AM
S&P Equity Research Lowers Repros Therapeutics Inc. (RPRX) Price Target to $0.39S&P Equity Research Lowers Repros Therapeutics Inc. (RPRX) Price Target to $0.39
www.americanbankingnews.com - November 20 at 4:14 PM
Repros Therapeutics Inc. (RPRX) Issues  Earnings Results, Beats Estimates By $0.24 EPSRepros Therapeutics Inc. (RPRX) Issues Earnings Results, Beats Estimates By $0.24 EPS
www.americanbankingnews.com - November 14 at 9:00 AM
Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial ... - GlobeNewswire (press release)Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial ... - GlobeNewswire (press release)
globenewswire.com - November 14 at 7:26 AM
Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial ResultsRepros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 7:26 AM
Repros Therapeutics reports 3Q lossRepros Therapeutics reports 3Q loss
finance.yahoo.com - November 14 at 7:26 AM
Repros Therapeutics reports Q3 resultsRepros Therapeutics reports Q3 results
seekingalpha.com - November 13 at 9:01 AM
Repros Therapeutics Inc. (RPRX) Short Interest UpdateRepros Therapeutics Inc. (RPRX) Short Interest Update
www.americanbankingnews.com - November 13 at 2:32 AM
What's in the Cards for Repros (RPRX) This Earnings Season?What's in the Cards for Repros (RPRX) This Earnings Season?
finance.yahoo.com - November 6 at 3:44 PM
Repros Therapeutics Inc. (RPRX) Scheduled to Post Earnings on MondayRepros Therapeutics Inc. (RPRX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - October 30 at 9:54 AM
Short Interest in Repros Therapeutics Inc. (RPRX) Grows By 155.5%Short Interest in Repros Therapeutics Inc. (RPRX) Grows By 155.5%
www.americanbankingnews.com - October 27 at 1:40 AM
3 Biotech Stocks to Have on Your Watch-List in October3 Biotech Stocks to Have on Your Watch-List in October
finance.yahoo.com - October 10 at 6:31 AM
Biotech Stocks on Investors Radar -- Neothetics, Pieris Pharma, and Repros Therapeutics - PR Newswire (press release)Biotech Stocks on Investors' Radar -- Neothetics, Pieris Pharma, and Repros Therapeutics - PR Newswire (press release)
www.prnewswire.com - September 27 at 11:23 PM
Contrasting Repros Therapeutics (RPRX) & Its RivalsContrasting Repros Therapeutics (RPRX) & Its Rivals
www.americanbankingnews.com - September 15 at 8:46 PM
CASI Pharmaceuticals (CASI) & Repros Therapeutics (RPRX) Critical ReviewCASI Pharmaceuticals (CASI) & Repros Therapeutics (RPRX) Critical Review
www.americanbankingnews.com - August 30 at 10:24 PM
Mid-Afternoon Market Update: Crude Oil Down 2%; Neff Shares Spike Higher - BenzingaMid-Afternoon Market Update: Crude Oil Down 2%; Neff Shares Spike Higher - Benzinga
www.benzinga.com - August 14 at 3:24 PM
Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 14 at 3:24 PM
Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial ResultsRepros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 14 at 3:24 PM
Repros Therapeutics reports 2Q lossRepros Therapeutics reports 2Q loss
finance.yahoo.com - August 14 at 3:24 PM
Repros Therapeutics Inc. (NASDAQ:RPRX) Issues Quarterly  Earnings ResultsRepros Therapeutics Inc. (NASDAQ:RPRX) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 14 at 10:47 AM
Short Interest in Repros Therapeutics Inc. (NASDAQ:RPRX) Drops By 47.7%Short Interest in Repros Therapeutics Inc. (NASDAQ:RPRX) Drops By 47.7%
www.americanbankingnews.com - August 13 at 2:20 AM
Repros (RPRX) Q2 Earnings: Whats in Store for the Stock? - NasdaqRepros (RPRX) Q2 Earnings: What's in Store for the Stock? - Nasdaq
www.nasdaq.com - August 2 at 7:17 AM
Repros (RPRX) Q2 Earnings: What's in Store for the Stock?Repros (RPRX) Q2 Earnings: What's in Store for the Stock?
finance.yahoo.com - August 2 at 7:17 AM
Repros Therapeutics Inc. (RPRX) Lowered to "Neutral" at LaidlawRepros Therapeutics Inc. (RPRX) Lowered to "Neutral" at Laidlaw
www.americanbankingnews.com - July 21 at 9:30 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc ... - PR Newswire (press release)SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc ... - PR Newswire (press release)
www.prnewswire.com - July 19 at 7:23 AM
Repros' Proellex Stays on Partial Clinical Hold, Shares FallRepros' Proellex Stays on Partial Clinical Hold, Shares Fall
finance.yahoo.com - July 19 at 7:22 AM
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Repros Therapeutics Inc.INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Repros Therapeutics Inc.
finance.yahoo.com - July 17 at 8:33 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. - RPRXSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. - RPRX
finance.yahoo.com - July 17 at 3:31 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc. (RPRX)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc. (RPRX)
finance.yahoo.com - July 17 at 3:31 PM

SEC Filings

Repros Therapeutics (NASDAQ:RPRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Repros Therapeutics (NASDAQ:RPRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Repros Therapeutics (NASDAQ RPRX) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.